论文部分内容阅读
Objective:To evaluate the efficacy and safety of leuprolide acetate in the treatment of endometriosis. Methods:The patients with endometriosis were randomly divided into leuprolide(n = 75) and control(n=74) groups.They were treated with either sustained-release injection of leuprolide acetate or Enatntone injection(control) for 3 times totally.After treatment,the ovarian mass volume was measured under B ultrasound.The changes in hormone levels of estrodial(E_2),FSH and LH,the pelvic signs,the scores of the patient’s subjective symptoms during menstruation and non-menstrual days were observed. Results:The rate of changes in ovarian mass volume had no statistically significant difference between the two groups(P=0.495-0.965).The average reduction of ovarian mass volume was 47.91%in leuprolide group,and 53.51%in the control group 12 weeks after first medication.The distinct improvement rate and improvement rate of total symptom scores during menstruation and non-menstrual days had no significant difference between the two groups.The hormone levels of E_2,FSH and LH were not significantly different between the two groups.The differences in the incidence of adverse reactions were not significant between the two groups. Conclusion:Leuprolide acetate produced by Livzon China is effective and safe in the treatment of endometriosis.
Objective: To evaluate the efficacy and safety of leuprolide acetate in the treatment of endometriosis. Methods: The patients with endometriosis were randomly divided into leuprolide (n = 75) and control (n = 74) groups. injection of leuprolide acetate or Enatntone injection (control) for 3 times totally. After treatment, the ovarian mass volume was measured under B ultrasound. changes in hormone levels of estrodial (E_2), FSH and LH, the pelvic signs, the scores of the patient’s subjective symptoms were menstruation and non-menstrual days were observed. Results: The rate of changes in ovarian mass volume had no statistically significant difference between the two groups (P = 0.495-0.965). The average reduction of ovarian mass volume was 47.91 % in leuprolide group, and 53.51% in the control group for 12 weeks after first medication. The distinct improvement rate and improvement rate of total symptom scores during menstruation and non-menstrual days had no sign ificant difference between the two groups. The hormone levels of E_2, FSH and LH were not significantly different between the two groups. The differences in the incidence of adverse reactions were not significant between the two groups. Conclusion: Leuprolide acetate produced by Livzon China is effective and safe in the treatment of endometriosis.